IN2012DN03362A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03362A
IN2012DN03362A IN3362DEN2012A IN2012DN03362A IN 2012DN03362 A IN2012DN03362 A IN 2012DN03362A IN 3362DEN2012 A IN3362DEN2012 A IN 3362DEN2012A IN 2012DN03362 A IN2012DN03362 A IN 2012DN03362A
Authority
IN
India
Prior art keywords
psoriasis
immune
treatment
antibodies against
humanized antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Roland Beckmann
Caroline Johnson-Leger
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of IN2012DN03362A publication Critical patent/IN2012DN03362A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3362DEN2012 2009-11-19 2010-11-12 IN2012DN03362A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
IN2012DN03362A true IN2012DN03362A (enExample) 2015-10-23

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3362DEN2012 IN2012DN03362A (enExample) 2009-11-19 2010-11-12

Country Status (20)

Country Link
US (1) US8545844B2 (enExample)
EP (1) EP2512511B1 (enExample)
JP (1) JP5818804B2 (enExample)
KR (1) KR20120098783A (enExample)
CN (1) CN102665759B (enExample)
AU (1) AU2010321047B2 (enExample)
BR (1) BR112012012003A2 (enExample)
CA (1) CA2778864C (enExample)
EA (1) EA021356B1 (enExample)
EC (1) ECSP12011980A (enExample)
ES (1) ES2531996T3 (enExample)
IL (1) IL219740A0 (enExample)
IN (1) IN2012DN03362A (enExample)
MX (1) MX2012005791A (enExample)
NZ (1) NZ599438A (enExample)
PE (1) PE20121560A1 (enExample)
PH (1) PH12012500924A1 (enExample)
UA (1) UA105405C2 (enExample)
WO (1) WO2011061119A1 (enExample)
ZA (1) ZA201202793B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) * 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN109153709B (zh) * 2016-03-18 2022-05-27 舒泰神（北京）生物制药股份有限公司 神经生长因子突变体
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN111032083B (zh) * 2017-05-24 2024-01-12 财团法人生物技术开发中心 抗globo h的人源化抗体及其在癌症治疗中的用途
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP2025520166A (ja) * 2022-06-03 2025-07-01 レオ ファーマ アクティーゼルスカブ Ｉｌ－２２ｒ抗体の液体製剤
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
BRPI0619118A2 (pt) * 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina

Also Published As

Publication number Publication date
ECSP12011980A (es) 2012-07-31
CN102665759B (zh) 2015-09-30
EA021356B1 (ru) 2015-05-29
US20120230990A1 (en) 2012-09-13
CN102665759A (zh) 2012-09-12
ZA201202793B (en) 2013-06-26
EP2512511B1 (en) 2015-01-07
IL219740A0 (en) 2012-07-31
EA201290360A1 (ru) 2012-11-30
PH12012500924A1 (en) 2012-11-26
CA2778864C (en) 2017-06-27
MX2012005791A (es) 2012-07-03
EP2512511A1 (en) 2012-10-24
AU2010321047B2 (en) 2016-06-09
UA105405C2 (ru) 2014-05-12
ES2531996T3 (es) 2015-03-23
KR20120098783A (ko) 2012-09-05
US8545844B2 (en) 2013-10-01
JP5818804B2 (ja) 2015-11-18
AU2010321047A1 (en) 2012-05-24
BR112012012003A2 (pt) 2016-11-29
NZ599438A (en) 2013-12-20
JP2013511267A (ja) 2013-04-04
CA2778864A1 (en) 2011-05-26
PE20121560A1 (es) 2012-12-05
WO2011061119A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
IN2012DN03362A (enExample)
GB201109238D0 (en) Antibodies
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2582722A4 (en) ANTIBODIES AGAINST GD2
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12013500703A1 (en) Human oncostatin m antibodies and methods of use
PH12012502215A1 (en) Anti-fgfr2 antibodies
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
MX2009011500A (es) Anticuerpos anti-mdl-1.
NZ599737A (en) Il-17a antagonists
IN2015DN02826A (enExample)
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EA201891594A1 (ru) Антитела к il-17c
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
WO2011019636A3 (en) Methods and compositions for the treatment of cancers and pathogenic infections
WO2012084993A3 (en) Biologically active oligonucleotides capable of modulating the immune system i
HK1190415A (en) Humanised anti-cd52 antibodies
UA112965C2 (uk) Гуманізоване антитіло до il-25
NZ757754A (en) Antibodies that bind csf1r
NZ622284A (en) Novel plant defensins and use in the treatment of proliferative diseases